Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor. The Company's product categories include Aesthetic Care, Skin Care, Wound Care and Non-Dermatology. The Company provides aesthetic dermatology solutions through thread lift, collagen stimulation and dermal fillers. The Company's aesthetic products include Silhouette Soft, Ellanse, Perfectha, Sculptra and USOFT Massage Gel. Its Silhouette Soft is inserted in the subcutaneous tissue. Its USOFT Massage Gel is a gel used for facial massage. It is engaged in research and development, and owns various product rights and licenses in a range of territories in which it trades.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Generic Pharmaceuticals
- Sub-Industry: N/A
- Symbol: LON:SPH
- CUSIP: N/A
- Web: www.sinclairispharma.com
- Market Cap: £134.34 million
- Outstanding Shares: 502,198,000
- 50 Day Moving Avg: GBX 29
- 200 Day Moving Avg: GBX 31.10
- 52 Week Range: GBX 26 - GBX 36.35
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £30.33 million
- Price / Sales: 4.43
- Book Value: GBX 0.20 per share
- Price / Book: 1.34
- EBIDTA: ($11,710,000.00)
- Net Margins: -42.69%
- Return on Equity: -16.64%
- Return on Assets: -9.47%
- Average Volume: 555,127 shs.
Frequently Asked Questions for Sinclair Pharma PLC (LON:SPH)
What is Sinclair Pharma PLC's stock symbol?
Sinclair Pharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "SPH."
Where is Sinclair Pharma PLC's stock going? Where will Sinclair Pharma PLC's stock price be in 2017?
6 brokerages have issued 12 month target prices for Sinclair Pharma PLC's shares. Their forecasts range from GBX 35 to GBX 71. On average, they anticipate Sinclair Pharma PLC's stock price to reach GBX 54 in the next year. View Analyst Ratings for Sinclair Pharma PLC.
Who are some of Sinclair Pharma PLC's key competitors?
Some companies that are related to Sinclair Pharma PLC include TSO3 (TOS), Alliance Pharma plc (APH), CareTech Holdings plc (CTH), SIGA Technologies (SIGA), Circassia Pharmaceuticals PLC (CIR), Faron Pharmaceuticals Oy (FARN), Mereo BioPharma Group PLC (MPH), Organovo Holdings (ONVO), Horizon Discovery Group PLC (HZD), OncoCyte Corp (OCX), Chromadex Corp (CDXC), Zymeworks (ZYME), Allergy Therapeutics plc (AGY), Transenterix (TRXC), Transenterix (TRXC), Kadmon Holdings (KDMN), Molecular Templates (MTEM) and Asterias Biotherapeutics (AST).
Who are Sinclair Pharma PLC's key executives?
Sinclair Pharma PLC's management team includes the folowing people:
- Christopher P. Spooner, Chief Executive Officer, Executive Director
- Alan Olby, Chief Financial Officer
- Jean-Louis Lamande, Operations Finance Director
- Jayne Burrell, Group General Counsel, Company Secretary
- Patrick Khoukaz, Head - European Operations and Global Aesthetics
- Sarb Klair, Head - Corporate Development
- Nairn McMaster, Head - Business Development
- Grahame David Cook, Non-Executive Independent Chairman of the Board
- Jean-Charles Tschudin, Senior Non-Executive Independent Director
How do I buy Sinclair Pharma PLC stock?
Shares of Sinclair Pharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Sinclair Pharma PLC's stock price today?
MarketBeat Community Rating for Sinclair Pharma PLC (LON SPH)MarketBeat's community ratings are surveys of what our community members think about Sinclair Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Sinclair Pharma PLC stock can currently be purchased for approximately GBX 26.75.
Consensus Ratings for Sinclair Pharma PLC (LON:SPH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 5 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.83)|
|Consensus Price Target: ||GBX 54|
Analysts' Ratings History for Sinclair Pharma PLC (LON:SPH)
(Data available from 9/21/2015 forward)
|9/19/2017||N+1 Singer||Reiterated Rating||Buy||GBX 37|
|9/19/2017||Peel Hunt||Reiterated Rating||Buy||GBX 68|
|7/11/2017||Stifel Nicolaus||Reiterated Rating||Buy||GBX 71|
|4/4/2017||Numis Securities Ltd||Reiterated Rating||Hold||GBX 35|
|3/22/2017||Jefferies Group LLC||Reiterated Rating||Buy||GBX 55|
|11/18/2016||Canaccord Genuity||Reiterated Rating||Buy||GBX 58|
|9/15/2016||Royal Bank Of Canada||Reiterated Rating||Outperform|
|9/28/2015||Panmure Gordon||Reiterated Rating||Under Review|
Earnings History for Sinclair Pharma PLC (LON:SPH)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Sinclair Pharma PLC (LON:SPH)
Current Year EPS Consensus Estimate: $-1.93 EPS
Dividend History for Sinclair Pharma PLC (LON:SPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sinclair Pharma PLC (LON:SPH)Insider Trades by Quarter for Sinclair Pharma PLC (LON:SPH)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/14/2016||Alan Olby||Insider||Buy||6,748||GBX 29||£1,956.92|
|10/4/2016||Jeff Thompson||Insider||Buy||150,000||GBX 29||£43,500|
Headline Trends for Sinclair Pharma PLC (LON:SPH)
Latest Headlines for Sinclair Pharma PLC (LON:SPH)
Sinclair Pharma PLC (SPH) Chart for Thursday, September, 21, 2017